JP2021514654A - Ｃｓｆ１ｒ結合剤 - Google Patents

Ｃｓｆ１ｒ結合剤 Download PDF

Info

Publication number
JP2021514654A
JP2021514654A JP2020545669A JP2020545669A JP2021514654A JP 2021514654 A JP2021514654 A JP 2021514654A JP 2020545669 A JP2020545669 A JP 2020545669A JP 2020545669 A JP2020545669 A JP 2020545669A JP 2021514654 A JP2021514654 A JP 2021514654A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020545669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514654A5 (https=
JPWO2019166596A5 (https=
Inventor
ジェームズ ジョナサン フィンレー，ウィリアム
ジェームズ ジョナサン フィンレー，ウィリアム
Original Assignee
ウルトラヒューマン トゥエルブ リミテッド
ウルトラヒューマン トゥエルブ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウルトラヒューマン トゥエルブ リミテッド, ウルトラヒューマン トゥエルブ リミテッド filed Critical ウルトラヒューマン トゥエルブ リミテッド
Publication of JP2021514654A publication Critical patent/JP2021514654A/ja
Publication of JP2021514654A5 publication Critical patent/JP2021514654A5/ja
Publication of JPWO2019166596A5 publication Critical patent/JPWO2019166596A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020545669A 2018-02-28 2019-02-28 Ｃｓｆ１ｒ結合剤 Pending JP2021514654A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1803226.8A GB201803226D0 (en) 2018-02-28 2018-02-28 CSF1R Binding agents
GB1803226.8 2018-02-28
GBGB1810226.9A GB201810226D0 (en) 2018-02-28 2018-06-21 CSF1R binding agents
GB1810226.9 2018-06-21
GB1819045.4 2018-11-22
GBGB1819045.4A GB201819045D0 (en) 2018-02-28 2018-11-22 Csf1r binding agents
PCT/EP2019/055077 WO2019166596A1 (en) 2018-02-28 2019-02-28 Csf1r binding agents

Publications (3)

Publication Number Publication Date
JP2021514654A true JP2021514654A (ja) 2021-06-17
JP2021514654A5 JP2021514654A5 (https=) 2022-03-09
JPWO2019166596A5 JPWO2019166596A5 (https=) 2022-03-09

Family

ID=61903334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020545669A Pending JP2021514654A (ja) 2018-02-28 2019-02-28 Ｃｓｆ１ｒ結合剤

Country Status (10)

Country Link
US (1) US11655300B2 (https=)
EP (1) EP3759137A1 (https=)
JP (1) JP2021514654A (https=)
CN (1) CN111788229A (https=)
AU (1) AU2019228110A1 (https=)
CA (1) CA3091307A1 (https=)
GB (3) GB201803226D0 (https=)
IL (1) IL276914A (https=)
SG (1) SG11202007837RA (https=)
WO (1) WO2019166596A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023547499A (ja) * 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
CN112472790B (zh) * 2020-12-25 2022-12-20 同济大学 小白蛋白的抑制剂在制备预防治疗肥胖以及肥胖导致的疾病产品中的用途
CN119019548B (zh) * 2022-07-05 2025-06-24 东莞市朋志生物科技有限公司 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140249A2 (en) * 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2262836T3 (da) * 2008-03-14 2016-04-04 Transgene Sa Antistof mod CSF-1R
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
RU2014136332A (ru) * 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140249A2 (en) * 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r

Also Published As

Publication number Publication date
CA3091307A1 (en) 2019-09-06
EP3759137A1 (en) 2021-01-06
WO2019166596A1 (en) 2019-09-06
IL276914A (en) 2020-10-29
CN111788229A (zh) 2020-10-16
GB201819045D0 (en) 2019-01-09
US20210301026A1 (en) 2021-09-30
GB201803226D0 (en) 2018-04-11
SG11202007837RA (en) 2020-09-29
GB201810226D0 (en) 2018-08-08
US11655300B2 (en) 2023-05-23
AU2019228110A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
US12173067B2 (en) C-KIT antibodies and method for treating cancer with such
JP7458569B2 (ja) Ｃｄ４７結合剤
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
US10858435B2 (en) PD1 binding agents
US12415861B2 (en) Anti C-MET antibodies
JP7419238B2 (ja) Ｐｄ１結合剤
US10975165B2 (en) De-immunised anti-ERBB3 antibodies
JP2021514654A (ja) Ｃｓｆ１ｒ結合剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231002